JJP Biologics acquires Recepton’s R&D facilities and antibody-engineering/ production expertise, strengthening discovery and R&D capabilities to support the growing innovative pipeline.
March 27, 2024
Warsaw, Poland – Three years after the establishment of the company, JJP Biologics signed the agreement to launch its own research laboratory which will support the JJP Biologics discovery pipeline. The concluded asset-based transaction results in the takeover of the biotechnology laboratory of Recepton and their experienced staff, which is located in the Gdańsk Science and Research Park.
“This transaction is another step in a consistently implemented plan to build a Polish biotech company in which world-class science is the determinant of development. The progress of scientific work achieved over the last two years on four drug programs in the JJP Biologics portfolio made the decision to create our own laboratory a natural one. An in-house biotechnology laboratory opens up new opportunities for a quick and effective verification of research hypotheses as well as in cooperation with research and academic groups around the world.” – Paweł Szczepański, Member of the Management Board of JJP Biologics.
The JJP Biologics research team will be expanded by 4 experienced specialists in the field of protein engineering and analytics. The Gdańsk laboratory is headed by Dr. Tomasz Sitar, Head of CMC JJP Biologics.
“Our own R&D laboratory specialized in protein engineering, production of recombinant antibodies and bioanalytics will allow for quick experimental verification and optimization of developed solutions, and thus increase the innovation potential of JJP Biologics to an even higher level.” – Tomasz Sitar, Head of CMC JJP Biologics.
Starting immediately, further experiments in the field of molecular biology (MB), protein production, innovative molecular design and cell line development (CLD) will be carried out in our own laboratory. In the coming months, further development of the laboratory is planned and the expansion of its activities to include Process Development Laboratory, the Antibody Development Laboratory and the Analytical and Stability Test Laboratory.
About JJP BIOLOGICS:
JJP Biologics is a pre-clinical and early-clinical stage biotechnology company that specializes in the development of therapeutic monoclonal antibodies accompanied by companion diagnostics for personalized treatment. JJP Biologics pursues the development of its own product candidates as well as projects executed in cooperation with scientific partners. The company’s programs target general immune pathways that have application in autoimmune diseases and cancer. JJP Biologics current range of programs includes the most advanced JJP-1212, a potential first-in-class CD89 antagonist for (auto)inflammatory diseases and JJP-1008, a potential first-in-class CD270 checkpoint inhibitor, for solid tumors. JJP Biologics is a privately funded biotech, partially financed from programs run by the Polish Medical Research Agency.
For more information visit www.jjpbiologics.com and join the #smartgoose community by following us on LinkedIn.
For further information, please contact: info@jjp.bio
